Document Detail

A randomised, controlled trial of bosentan in severe COPD.
MedLine Citation:
PMID:  18448495     Owner:  NLM     Status:  MEDLINE    
Pulmonary hypertension during exercise is common in severe chronic obstructive pulmonary disease (COPD). It was hypothesised that the use of the endothelin-receptor antagonist bosentan can improve cardiopulmonary haemodynamics during exercise, thus increasing exercise tolerance in patients with severe COPD. In the present double-blind, placebo-controlled study, 30 patients with severe or very severe COPD were randomly assigned in a 2:1 ratio to receive either bosentan or placebo for 12 weeks. The primary end-point was change in the 6-min walking distance. Secondary end-points included changes in health-related quality of life, lung function, cardiac haemodynamics, maximal oxygen uptake and pulmonary perfusion patterns. Compared with placebo, patients treated with bosentan during 12 weeks showed no significant improvement in exercise capacity as measured by the 6-min walking distance (mean+/-SD 331+/-123 versus 329+/-94 m). There was no change in lung function, pulmonary arterial pressure, maximal oxygen uptake or regional pulmonary perfusion pattern. In contrast, arterial oxygen pressure dropped, the alveolar-arterial gradient increased and quality of life deteriorated significantly in patients assigned bosentan. The oral administration of the endothelin receptor antagonist bosentan not only failed to improve exercise capacity but also deteriorated hypoxaemia and functional status in severe chronic obstructive pulmonary disease patients without severe pulmonary hypertension at rest.
D Stolz; H Rasch; A Linka; M Di Valentino; A Meyer; M Brutsche; M Tamm
Related Documents :
10802005 - Ventilatory response to exercise in patients with major aortopulmonary collateral arter...
19324955 - Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic ...
9091525 - Cardiorespiratory response to exercise after modified fontan operation: determinants of...
3341635 - Lack of radiographic evidence of interstitial pulmonary edema after maximal exercise in...
12830975 - Functional electrical stimulation for walking in paraplegia: 17-year follow-up of 2 cases.
22212885 - Complex obstacle negotiation exercise can prevent falls in community-dwelling elderly j...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2008-04-30
Journal Detail:
Title:  The European respiratory journal     Volume:  32     ISSN:  1399-3003     ISO Abbreviation:  Eur. Respir. J.     Publication Date:  2008 Sep 
Date Detail:
Created Date:  2008-09-01     Completed Date:  2009-01-13     Revised Date:  2013-06-18    
Medline Journal Info:
Nlm Unique ID:  8803460     Medline TA:  Eur Respir J     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  619-28     Citation Subset:  IM    
Clinic of Pulmonary Medicine and Respiratory Cell Research, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Double-Blind Method
Exercise Tolerance / drug effects
Hypertension, Pulmonary / complications*,  drug therapy*
Middle Aged
Pulmonary Disease, Chronic Obstructive / complications*,  pathology
Quality of Life
Sulfonamides / adverse effects*
Vasodilator Agents / adverse effects*
Reg. No./Substance:
0/Sulfonamides; 0/Vasodilator Agents; Q326023R30/bosentan
Comment In:
Eur Respir J. 2009 Feb;33(2):449; author reply 452-3   [PMID:  19181925 ]
Eur Respir J. 2008 Sep;32(3):541-2   [PMID:  18757693 ]
Eur Respir J. 2009 Feb;33(2):449-50; author reply 452-3   [PMID:  19181924 ]
Eur Respir J. 2009 Feb;33(2):450-2; author reply 452-3   [PMID:  19181926 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The association between HIV and antituberculosis drug resistance.
Next Document:  Determinants of hospital costs in community-acquired pneumonia.